Početna stranicaBHC • NYSE
add
Valeant Pharmaceuticals
Preth. zaklj. cijena
7,88 $
Dnevni raspon
7,45 $ - 7,80 $
Godišnji raspon
3,96 $ - 11,46 $
Tržišna kapitalizacija
2,74 mlr. USD
Prosječna količina
1,27 mil.
P/E omjer
-
Prinos dividende
-
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 2,51 mlr. | 12,15 % |
Operativni troškovi | 1,27 mlr. | 13,29 % |
Neto dohodak | −85,00 mil. | 77,51 % |
Neto profitabilnost | −3,39 | 79,93 % |
Zarada po dionici | 1,12 | 9,34 % |
EBITDA | 866,00 mil. | 8,93 % |
Efektivna porezna stopa | −338,10 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 719,00 mil. | −5,39 % |
Ukupna imovina | 26,54 mlr. | −1,94 % |
Ukupne obveze | 26,78 mlr. | −1,89 % |
Ukupni kapital | −242,00 mil. | — |
Dionice u optjecaju | 367,80 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | −2,47 | — |
Povrat imovine | 5,13 % | — |
Povrat kapitala | 6,37 % | — |
Tok novca
Neto promjena novca
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −85,00 mil. | 77,51 % |
Gotovina od poslovanja | 405,00 mil. | 43,62 % |
Gotovina iz ulaganja | −102,00 mil. | 94,60 % |
Gotovina iz financiranja | −189,00 mil. | −110,41 % |
Neto promjena novca | 127,00 mil. | −33,85 % |
Slobodan tok novca | 606,75 mil. | 261,43 % |
Više
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Glavni izvršni direktor
Osnovano
1959
Sjedište
Web-lokacija
Zaposlenici
20.270